Does Semaglutide Affect Libido — and What Does the Evidence Actually Show?

What the licensed trial data (and its gaps) actually tell us

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults and ran for 68 weeks. It produced robust data on weight, cardiometabolic markers and quality-of-life scores. Libido was not a named endpoint. This is not unusual, most large weight-management trials prioritise hard clinical outcomes, and sexual function questionnaires are resource-intensive to administer and interpret. The absence of a dedicated libido finding is therefore a data gap, not a verdict of safety or harm.

The Wegovy SmPC (the prescribing document that lists known side effects based on all submitted trial data) does not include altered libido or sexual dysfunction among the recognised adverse effects. That matters. It means the pharmacovigilance data gathered across tens of thousands of patient-months did not reveal a strong enough signal to meet the threshold for labelling. However, the SmPC reflects what was measured; it cannot rule out effects that were not systematically assessed. Reviewing the NHS semaglutide medicines page confirms the same picture: reproductive or sexual effects are absent from the documented side-effect list.

So does semaglutide affect libido? Formally, there is no confirmed direct pharmacological link. Practically, the story is more layered than that.

How weight loss itself reshapes sexual function, the indirect route

A question our prescribers hear most weeks is whether the medicine is responsible for any libido change, when the change could equally be driven by what the medicine achieves. Significant weight reduction alters sex hormone levels in clinically meaningful ways: in men, adipose tissue converts testosterone to oestrogen via aromatase, so losing fat mass tends to raise free testosterone; in women, obesity is associated with lower testosterone and disrupted oestrogen patterns, and weight loss can partially normalise both.

Beyond hormones, improved cardiovascular fitness, reduced joint pain, better sleep and lower inflammation all contribute to energy and sexual confidence. These are slow, cumulative effects. They do not appear in week four of treatment; they build over months, alongside weight loss itself. For a fuller look at how semaglutide interacts with sleep specifically, the evidence on semaglutide and sleep quality covers a related set of questions about indirect physiological effects.

The upshot: for many people, any libido shift on Wegovy turns out to be positive over time, not because the molecule has a pro-libido action, but because the downstream effects of losing a meaningful amount of weight do. That is not guaranteed, and individual biology varies considerably.

Side effects that can temporarily affect sexual interest

The gastrointestinal phase of starting or increasing semaglutide is real. Nausea, fatigue and occasional low mood are among the common effects listed on the NHS semaglutide page, especially in the weeks following a dose increase. Feeling persistently nauseated does not leave much room for desire. These effects are generally transient (most people find they settle within one to two weeks) but during that window, a reduction in libido would be unsurprising and is not evidence of a lasting change.

There is also the question of mood. Does wegovy affect your libido through psychological channels? Possibly. Weight stigma, body image and the emotional weight of long-term obesity are real burdens. Starting treatment can bring relief, but it can also stir complicated feelings about body and identity. That psychological dimension is not well captured in clinical trial data. If low mood feels persistent rather than fluctuating, it warrants a prescriber conversation, not least because mood changes are worth monitoring separately on any long-term treatment.

For people interested in the broader picture of how semaglutide affects key biological markers, the page on semaglutide's effects on blood work covers what the evidence shows for cholesterol, liver enzymes and hormone-related measures.

What this means if you are considering or already taking Wegovy

Wegovy is licensed in the UK for weight management in adults with a BMI of 30 or above, or from 27 with at least one weight-related health condition, alongside a reduced-calorie diet and increased activity. You can find more detail on the treatment itself on the Wegovy treatment page, including how the dosing schedule works from the prescriber's perspective. Costs and what a private prescription includes are covered on the Wegovy pricing page if you are weighing up whether private treatment makes sense for your situation.

On the libido question specifically: if you are currently taking Wegovy and have noticed a change (in either direction) it is worth logging when it started relative to your dose schedule. Changes appearing shortly after a dose increase and resolving within a few weeks are most likely GI-phase fatigue effects. Changes that persist, are distressing or coincide with mood shifts are worth discussing with your prescriber directly rather than attributing to treatment and moving on.

The full guide to Wegovy and libido explores this in more depth, including the specific evidence around testosterone and oestrogen shifts during weight loss treatment. Women-specific considerations are covered separately on how Wegovy may affect libido in women. If questions about semaglutide and blood sugar are relevant to your health background, that evidence is set out on this page about semaglutide's effects on blood glucose.

If you are thinking about starting treatment and want a clinician to look at your full picture, speak to our prescribers, every consultation at nume is reviewed the same day by a GPhC-registered Independent Prescriber, not a queue and not software.